$279 Million is the total value of Affinity Asset Advisors, LLC's 69 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPDR SER TRput | $27,080,000 | – | 200,000 | +100.0% | 9.69% | – |
| CVAC | New | CUREVAC N Vput | $11,022,000 | – | 150,000 | +100.0% | 3.95% | – |
| NAUT | New | NAUTILUS BIOTECHNOLOGY INC | $9,090,000 | – | 900,000 | +100.0% | 3.25% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INCcall | $4,238,000 | – | 25,000 | +100.0% | 1.52% | – |
| IONS | New | IONIS PHARMACEUTICALS INCcall | $2,992,000 | – | 75,000 | +100.0% | 1.07% | – |
| MSAC | New | MEDICUS SCIENCES ACQUISITION | $2,895,000 | – | 300,000 | +100.0% | 1.04% | – |
| SDGR | New | SCHRODINGER INC | $1,890,000 | – | 25,000 | +100.0% | 0.68% | – |
| NTLA | New | INTELLIA THERAPEUTICS INC | $1,619,000 | – | 10,000 | +100.0% | 0.58% | – |
| New | GOSSAMER BIO INCnote 5.000% 6/0 | $1,605,000 | – | 2,000,000 | +100.0% | 0.58% | – | |
| CNTA | New | CENTESSA PHARMACEUTICALS PLCsponsored ads | $1,487,000 | – | 66,957 | +100.0% | 0.53% | – |
| CGEM | New | CULLINAN ONCOLOGY INC | $1,159,000 | – | 45,000 | +100.0% | 0.42% | – |
| NSTG | New | NANOSTRING TECHNOLOGIES INC | $972,000 | – | 15,000 | +100.0% | 0.35% | – |
| QSI | New | QUANTUM SI INC | $920,000 | – | 75,000 | +100.0% | 0.33% | – |
| ITOS | New | ITEOS THERAPEUTICS INC | $641,000 | – | 25,000 | +100.0% | 0.23% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $632,000 | – | 10,000 | +100.0% | 0.23% | – |
| SKINW | New | THE BEAUTY HEALTH COMPANY*w exp 05/04/2026 | $288,000 | – | 45,000 | +100.0% | 0.10% | – |
| CVRX | New | CVRX INC | $210,000 | – | 7,500 | +100.0% | 0.08% | – |
| MSACW | New | MEDICUS SCIENCES ACQUISITION*w exp 02/12/2026 | $34,000 | – | 33,333 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MORPHIC HOLDING INC | 12 | Q3 2023 | 6.9% |
| KURA ONCOLOGY INC | 12 | Q3 2023 | 7.2% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 1.9% |
| IMMATICS N.V | 12 | Q3 2023 | 0.4% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.4% |
| ESTABLISHMENT LABS HLDGS INC | 11 | Q3 2023 | 8.3% |
| VINCERX PHARMA INC | 11 | Q2 2023 | 4.5% |
| ASCENDIS PHARMA A/S | 11 | Q3 2023 | 4.9% |
| CYTOKINETICS INC | 11 | Q3 2023 | 2.6% |
| INARI MED INC | 10 | Q1 2023 | 6.4% |
View Affinity Asset Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 03, 2023 | 7,477,000 | 9.2% |
View Affinity Asset Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-21 |
| 13F-HR | 2023-08-14 |
| SC 13G | 2023-07-03 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-13 |
View Affinity Asset Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.